Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SHE:002675)
13.52
+0.02 (0.15%)
Feb 3, 2026, 3:04 PM CST
SHE:002675 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,726 | 2,846 | 3,267 | 3,565 | 3,897 | 3,402 |
Other Revenue | 23.35 | 23.35 | 8.24 | 18.34 | 15.02 | 16.85 |
| 2,750 | 2,869 | 3,276 | 3,583 | 3,912 | 3,419 | |
Revenue Growth (YoY) | -3.62% | -12.42% | -8.58% | -8.41% | 14.42% | 14.24% |
Cost of Revenue | 1,360 | 1,521 | 1,922 | 2,051 | 2,324 | 1,756 |
Gross Profit | 1,390 | 1,348 | 1,354 | 1,532 | 1,588 | 1,663 |
Selling, General & Admin | 765.05 | 724.93 | 754.41 | 785.29 | 802.41 | 889.04 |
Research & Development | 300.36 | 291.91 | 197.22 | 163.52 | 137.56 | 109.39 |
Other Operating Expenses | 35.53 | 31.76 | 33.87 | 29.19 | 33.34 | 30.95 |
Operating Expenses | 1,113 | 1,065 | 980.31 | 980.56 | 974.77 | 1,038 |
Operating Income | 276.73 | 282.61 | 373.77 | 551.72 | 612.99 | 625.11 |
Interest Expense | -122.43 | -96.51 | -56.76 | -58.64 | -56.45 | -47.8 |
Interest & Investment Income | 5.79 | 5.56 | 12.78 | 13.2 | 5.12 | 12.25 |
Currency Exchange Gain (Loss) | 15.44 | 15.44 | 15.25 | 42.65 | -4.08 | -3.67 |
Other Non Operating Income (Expenses) | 0.97 | -2.79 | -1.17 | -5.94 | -2.58 | -3.69 |
EBT Excluding Unusual Items | 176.51 | 204.31 | 343.86 | 542.97 | 555 | 582.2 |
Impairment of Goodwill | -52.6 | -52.6 | - | -80.1 | -211.26 | - |
Gain (Loss) on Sale of Investments | -15.81 | -12.92 | -28.13 | -39.21 | -12.15 | 1.05 |
Gain (Loss) on Sale of Assets | 0.33 | 0.21 | -0.23 | -0.38 | -0.15 | -1.29 |
Asset Writedown | -35.38 | -33.21 | - | - | -0.16 | -0.32 |
Other Unusual Items | 113.31 | 113.31 | 21.77 | 22.3 | 24.82 | 29.74 |
Pretax Income | 186.35 | 219.1 | 337.28 | 445.58 | 356.1 | 611.37 |
Income Tax Expense | 72.02 | 77.68 | 83.07 | 92.75 | 95.25 | 93.9 |
Earnings From Continuing Operations | 114.32 | 141.43 | 254.22 | 352.83 | 260.85 | 517.47 |
Minority Interest in Earnings | 51.75 | 42.4 | -44.48 | -45.54 | -109.29 | -99.71 |
Net Income | 166.07 | 183.83 | 209.74 | 307.29 | 151.56 | 417.77 |
Net Income to Common | 166.07 | 183.83 | 209.74 | 307.29 | 151.56 | 417.77 |
Net Income Growth | 82.92% | -12.35% | -31.75% | 102.75% | -63.72% | 170.02% |
Shares Outstanding (Basic) | 825 | 825 | 825 | 808 | 802 | 802 |
Shares Outstanding (Diluted) | 825 | 825 | 825 | 808 | 802 | 802 |
Shares Change (YoY) | 0.04% | -0.01% | 2.10% | 0.68% | 0.01% | 0.02% |
EPS (Basic) | 0.20 | 0.22 | 0.25 | 0.38 | 0.19 | 0.52 |
EPS (Diluted) | 0.20 | 0.22 | 0.25 | 0.38 | 0.19 | 0.52 |
EPS Growth | 82.85% | -12.35% | -33.15% | 101.38% | -63.73% | 169.97% |
Free Cash Flow | 158.02 | -168.94 | -235 | 606.93 | 413.42 | 310.39 |
Free Cash Flow Per Share | 0.19 | -0.20 | -0.28 | 0.75 | 0.52 | 0.39 |
Dividend Per Share | 0.030 | 0.080 | 0.125 | 0.150 | 0.150 | 0.250 |
Dividend Growth | -82.86% | -36.00% | -16.67% | - | -40.00% | - |
Gross Margin | 50.54% | 46.97% | 41.34% | 42.77% | 40.59% | 48.65% |
Operating Margin | 10.06% | 9.85% | 11.41% | 15.40% | 15.67% | 18.28% |
Profit Margin | 6.04% | 6.41% | 6.40% | 8.58% | 3.87% | 12.22% |
Free Cash Flow Margin | 5.75% | -5.89% | -7.17% | 16.94% | 10.57% | 9.08% |
EBITDA | 435.93 | 432.69 | 511.69 | 672.09 | 727.92 | 727.85 |
EBITDA Margin | 15.85% | 15.08% | 15.62% | 18.76% | 18.61% | 21.29% |
D&A For EBITDA | 159.2 | 150.08 | 137.92 | 120.37 | 114.93 | 102.74 |
EBIT | 276.73 | 282.61 | 373.77 | 551.72 | 612.99 | 625.11 |
EBIT Margin | 10.06% | 9.85% | 11.41% | 15.40% | 15.67% | 18.28% |
Effective Tax Rate | 38.65% | 35.45% | 24.63% | 20.82% | 26.75% | 15.36% |
Revenue as Reported | 2,750 | 2,869 | 3,276 | 3,583 | 3,912 | 3,419 |
Advertising Expenses | - | 0.5 | 1.06 | 0.83 | 0.29 | 0.15 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.